Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer now directly owns 660,482 shares of the company's stock, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kymera Therapeutics Trading Up 0.0%
NASDAQ KYMR traded up $0.02 during trading on Friday, hitting $47.68. 467,691 shares of the company traded hands, compared to its average volume of 608,438. The company has a market capitalization of $3.10 billion, a P/E ratio of -20.36 and a beta of 2.07. The business has a fifty day simple moving average of $29.81 and a 200 day simple moving average of $35.74. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. During the same period in the previous year, the company earned ($0.69) EPS. The company's revenue for the quarter was up 114.6% on a year-over-year basis. Equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Institutional Trading of Kymera Therapeutics
Large investors have recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. State of Wyoming acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $45,000. GF Fund Management CO. LTD. bought a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV grew its stake in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after acquiring an additional 328 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics in the first quarter worth $68,000.
Analyst Ratings Changes
KYMR has been the subject of a number of recent analyst reports. Morgan Stanley raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $49.00 to $79.00 in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a report on Tuesday. HC Wainwright upped their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a research report on Monday. Finally, Stifel Nicolaus started coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price on the stock. Two research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $59.82.
Check Out Our Latest Stock Report on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Further Reading
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
